An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans.
Kurtz CB, Millet YA, Puurunen MK, Perreault M, Charbonneau MR, Isabella VM, Kotula JW, Antipov E, Dagon Y, Denney WS, Wagner DA, West KA, Degar AJ, Brennan AM, Miller PF.
Kurtz CB, et al.
Sci Transl Med. 2019 Jan 16;11(475):eaau7975. doi: 10.1126/scitranslmed.aau7975.
Sci Transl Med. 2019.
PMID: 30651324
Clinical Trial.
SYNB1020 produced l-arg and consumed NH(3) in an in vitro system. SYNB1020 reduced systemic hyperammonemia, improved survival in ornithine transcarbamylase-deficient spf(ash) mice, and decreased hyperammonemia in the thioacetamide-induced liver injury mouse m …
SYNB1020 produced l-arg and consumed NH(3) in an in vitro system. SYNB1020 reduced systemic hyperammonemia, improved survival in o …